Etonogestrel with ethinylestradiol

PBAC's latest decision on Etonogestrel with ethinylestradiol: Deferred (2025). Considered for Contraception for women seeking a non-oral contraceptive preparation who have difficulty swallowing tablets, gastrointestinal disturbances (e.g. malabsorption), or undesirable side effects with oral contraceptives.

Eligible population

Women seeking contraception who meet at least one of the following criteria: difficulty swallowing tablets, gastrointestinal disturbances (e.g. malabsorption), or undesirable side effects with oral contraceptives.

Therapy area

Women's health

Line of therapy

Not applicable

Evidence base

Cost-minimisation

Primary endpoint

Cost-minimisation

Comparator

depot medroxyprogesterone acetate injection (DMPA)

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis approach used; no ICER calculated as per cost-minimisation methodology.

Similar precedents

• Medroxyprogesterone acetate
  similarity 0.69
• Drospirenone
  similarity 0.66
• Estetrol with drospirenone
  similarity 0.65
• Estradiol with progesterone
  similarity 0.64
• Progesterone
  similarity 0.64
• Levonorgestrel
  similarity 0.63